{
  "title": "M21-1, Part V, Subpart iii, Chapter 3 - Infectious Diseases, Immune Disorders, and Nutritional Deficiencies",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014467/M21-1-Part-V-Subpart-iii-Chapter-3-Infectious-Diseases-Immune-Disorders-and-Nutritional-Deficiencies",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Chapter\nThis chapter contains the following topics:\nTopic\nTopic Name\n1\nGeneral Rating Principles for Infectious Diseases, Immune Disorders, and Nutritional Deficiencies\n2\nTropical Diseases\n3\nRhuematic Fever\n4\nHuman Immunodeficiency Virus (HIV)-Related Illness\n5\nChronic Fatigue Syndrome\n6\nNovel Coronavirus Infection (COVID-19)\n1\n.\nGeneral Rating Principles for Infectious Diseases, Immune Disorders, and Nutritional Deficiencies\nIntroduction\nThis topic contains information about the general rating principles for infectious diseases, immune disorders, and nutritional deficiencies, including\ndefinition of\ninfectious diseases\nimmune disorders\n, and\nnutritional deficiencies\nrevisions of the infectious diseases, immune disorders, and nutritional deficiencies rating schedule\nevaluations under the infectious diseases general rating formula\n, and\nevaluating long-term health effects of 38 CFR 3.317 infectious diseases\n.\nChange Date\nAugust 12, 2019\nV.iii.3.1.a\n.\nDefinition:  Infectious Diseases\nInfectious diseases\nare disorders caused by organisms, such as bacteria, viruses, fungi, or parasites.\nExample\n:  Malaria.\nNote\n:  Consider presumptive service connection (SC) for infectious diseases listed in\n38 CFR 3.309(b)\nbased on tropical service\n38 CFR 3.309(c)\nbased on confirmed former prisoner of war (FPOW) status, and\n38 CFR 3.317(c)\nbased on service in the Southwest Asia theater of operations during the Gulf War or on or after September 19, 2001, in Afghanistan.\nReferences\n:  For more information on presumptive SC for\ntropical diseases, see\nM21-1, Part VIII, Subpart iii, 1\nFPOW disabilities, see\nM21-1, Part VIII, Subpart iv, 2.D\n, and\ninfectious diseases under\n38 CFR 3.317\n, see\nM21-1, Part VIII, Subpart ii, 1.A.1.p\n.\nV.iii.3.1.b\n.\nDefinition:  Immune Disorders\nImmune\ndisorders\ncause abnormally low activity or overactivity of the immune system.  In cases of immune system overactivity, the body attacks and damages its own tissues (autoimmune diseases).  Immune deficiency diseases decrease the body's ability to fight invaders, causing vulnerability to infections.  Immune disorders can be caused by organisms, use of medications, or other chronic conditions.\nExample\n:  Systemic lupus erythematosus.\nNote\n:  Consider presumptive SC for immune disorders listed in\n38 CFR 3.309(a)\n.\nV.iii.3.1.c\n.\nDefinition:  Nutritional Deficiencies\nNutritional deficiencies\noccur when the body is unable to obtain the necessary amount of a nutrient that is required for proper health.  These deficiencies can be caused by diet, surgical residuals, genetics, environment, or other diseases.\nExample\n:  Beriberi.\nNote\n:  Consider presumptive SC for disabilities listed in SC\n38 CFR 3.309(c)\nbased on based on confirmed FPOW status.\nReference\n:  For more information on presumptive SC for FPOW disabilities, see\nM21-1, Part VIII, Subpart iv, 2.D.3\n.\nV.iii.3.1.d\n.\nRevisions of the Infectious Diseases, Immune Disorders, and Nutritional Deficiencies Rating Schedule\nThe criteria for rating disabilities based on infectious diseases, immune disorders, and nutritional deficiencies in\n38 CFR 4.88b\nwere most recently updated effective\nAugust 11, 2019, and\nAugust 30, 1996.\nThe purpose of these updates was to\nincorporate medical advances\nupdate medical terminology\nadd disabilities not previously included, and\nrefine rating criteria.\nNote\n:  These updates were not liberalizing changes in the rating criteria.\nReferences\n:  For more information on\nthese and other historical changes to\n38 CFR 4.88b\n, see\n38 CFR 4, Appendix A\n38 CFR 4.88b\n(Historical), and\nthe\nBoard of Veterans Appeal Research Tools\nwebsite for historical\n38 CFR 4.88b\n, and\neffect of rating schedule readjustment, see\nM21-1, Part V, Subpart ii, 3.D.2.i\n.\nV.iii.3.1.e\n.\nEvaluations Under the Infectious Diseases General Rating Formula\nPrior to the August 11, 2019, rating schedule revision, each infectious disease listed under\n38 CFR 4.88b\nhad its own prescribed rating criteria.\nEffective August 11, 2019,\n38 CFR 4.88b\ncontains a general rating formula applicable to multiple infectious diseases, regardless of etiology.\nFor each diagnostic code (DC) that refers to this general rating formula, decision makers must\nassign the prescribed evaluation during the active disease phase, and thereafter,\nassign\na 0-percent evaluation for the infectious disease under the relevant\n38 CFR 4.88b\nDC, and\nevaluations for any residual disability of the infection within the appropriate body system as indicated by the notes in the evaluation criteria.\nNotes\n:\nRegardless of whether resolution occurs spontaneously or because of treatment, long-term disability in such situations results from residual functional impairment of the body systems affected by the infectious disease, rather than the infection itself.\nInfectious diseases for both the initial diagnosis and any relapse of active infection must be confirmed by diagnostic testing specific to the disease.\nV.iii.3.1.f\n.\nEvaluating Long-Term Health Effects of 38 CFR 3.317 Infectious Diseases\nAs applicable, consider the long-term health effects potentially associated with infectious diseases as listed in\n38 CFR 3.317(d)\n, specifically for brucellosis, Campylobacter jejuni, Coxiella burnetii (Q fever), malaria, Mycobacterium tuberculosis, nontyphoid Salmonella, Shigella, visceral leishmaniasis, and West Nile virus.\nReference\n:  For more information on presumptive SC for infectious diseases under\n38 CFR 3.317\n, see\nM21-1, Part VIII, Subpart ii, 1.A.1.p\n.\n2\n.\nTropical Diseases\nIntroduction\nThis topic contains information about tropical diseases, including\nspecific tropical diseases\nobtaining information about tropical diseases\nincubation periods of tropical diseases\n, and\nconsidering SC for tropical diseases not of record\n.\nChange Date\nDecember 13, 2005\nV.iii.3.2.a\n.\nSpecific Tropical Diseases\nThe following tropical diseases, among others, may require attention in view of their incidence in areas of foreign service:\nbacterial infections, including\nbacillary dysentery\ncholera\nHansen’s disease (leprosy)\nOroya fever\npinta\nplague\nrelapsing fever, and\nyaws\nviral infections, including yellow fever\nroundworm parasitic infections, including\ndracontiasis\nfilariasis (Bancroft’s type)\nhookworm infection\nloiasis, and\nonchocerciasis\nother parasitic infections, including\namebiasis\nblackwater fever\nleishmaniasis\nmalaria, and\nschistosomiasis.\nNotes\n:\nRate amebiasis and schistosomiasis under the digestive system.\nRate pinta, verruga peruana (a late residual of Oroya fever), onchoceriasis, oriental sore, and espundia (Old World cutaneous and American (New World) mucocutaneous leishmaniasis) under diseases of the skin.\nReference\n:  For more information on tropical diseases, see\n38 CFR 3.307(a)(4)\n38 CFR 3.309(b)\n, and\nM21-1, Part VIII, Subpart iii, 1\n.\nV.iii.3.2.b\n.\nObtaining Information about Tropical Diseases\nAn understanding of the locality, incubation period, and residuals of tropical diseases may be obtained from standard treatises.\nReference\n: For more information on tropical diseases, see\nThe Merck Manual of Diagnosis and Therapy\n.\nV.iii.3.2.c\n.\nIncubation Periods of Tropical Diseases\nThe table below contains the incubation periods of some tropical diseases.\nTropical Disease\nIncubation Period\ndracontiasis (Guinea worm disease)\n14 months\nfilariasis, Bancroft’s type\nup to 8 to 12 months\nkala-azar (visceral leishmaniasis)\nup to one year\nHansen’s disease (leprosy)\nfive years or more\nloiasis, calabar swelling\nthree years\noriental sore, Old World cutaneous leishmaniasis\nup to 18 months\nV.iii.3.2.d\n.\nConsidering SC for Tropical Diseases Not of Record\nWhen considering SC for tropical diseases\nnot\nof record during service always\nconsider tropical residence other than that during military service, and\nconsult standard texts for disease factors, such as\nlocality of confinement\nearly symptoms\ncourse of the disease, and\nperiods of incubation.\nReference\n:\nFor more information on developing claims for SC for tropical diseases, see\nM21-1, Part VIII, Subpart iii, 1\n.\n3\n.\nRheumatic Fever\nIntroduction\nThis topic contains information about rheumatic fever, including\ndefinition of rheumatic fever\ncomplications of rheumatic fever\nthe prognosis of rheumatic fever\n, and\nconsidering the effects of rheumatic heart disease\n.\nChange Date\nDecember 13, 2005\nV.iii.3.3.a\n.\nDefinition: Rheumatic Fever\nRheumatic fever is an acute, subacute, or chronic systemic disease that, for unknown reasons, is self-limiting or may lead to slowly progressive valve deformity of the heart.\nReference\n:  For more information on evaluating rheumatic fever, see\n38 CFR 4.88b, DC 6309\n.\nV.iii.3.3.b\n.\nComplications of Rheumatic Fever\nComplications of rheumatic fever include\ncardiac arrhythmias\npericarditis\nrheumatic pneumonitis\npulmonary embolism\npulmonary infarction\nvalve deformity, and\nin extreme cases, congestive heart failure.\nV.iii.3.3.c\n.\nPrognosis of Rheumatic Fever\nThe prognosis is good in cases of rheumatic fever.\nIf the age of onset is postadolescence, residual heart damage\noccurs in less than 20 percent of the cases, and\nis generally less severe than if the onset is during childhood.\nNote\n:\nMitral valve insufficiency is the most common residual.\nV.iii.3.3.d\n.\nConsidering the Effects of Rheumatic Heart Disease\nFor more information on the effects of rheumatic heart disease, see\n38 CFR 4.104, DC 7000\n, and\nM21-1, Part V, Subpart iii, 5.1.g\n.\n4\n.\nHIV-Related Illness\nIntroduction\nThis topic contains information about HIV-related illness, including\ndefinition of\nHIV\n, and\nacquired immunodeficiency syndrome (AIDS)\nhow HIV infection is diagnosed\ndefinition of CD4 T cells\nHIV transmission\ndefinition of approved medication(s)\nrating considerations for HIV-related illness\n, and\nrating AIDS\n.\nChange Date\nAugust 12, 2019\nV.iii.3.4.a\n.\nDefinition:\nHIV\nHuman immunodeficiency virus\n(HIV) is spread through body fluids that affect specific cells of the immune system, called CD4 cells, or T cells.  Over time, HIV can destroy so many of these cells that the body cannot fight off infections and disease.\nReference\n:  For more information on rating HIV, see\n38 CFR 4.88b\n, and\nM21-1, Part V, Subpart iii, 3.4.g\n.\nV.iii.3.4.b\n.\nDefinition:  AIDS\nAcquired immunodeficiency syndrome\n(AIDS) is a secondary infection and results from HIV infection.  It is not a single distinct disease, but rather a disorder characterized by a severe suppression of the immune system, rendering the body susceptible to and unable to fight off a variety of normally manageable infections, cancers, and other diseases.\nPatients with AIDS suffer infections called “opportunistic” because they take the opportunity to attack when the immune system is weak.  This may involve the intestinal tract, lungs, brain, eyes and other organs, as well as debilitating weight loss, diarrhea, and neurologic conditions.\nImportant\n:  If a Veteran has HIV and one or more of the following opportunistic infections, regardless of the CD4 (T4) count, the Veteran is considered to have a diagnosis of AIDS:\ncandidiasis of the bronchi, trachea, esophagus, or lungs\ninvasive cervical cancer\ncoccidioidomycosis\ncryptococcosis\ncryptosporidiosis\ncytomegalovirus (particularly CMV retinitis)\nHIV-related encephalopathy\nherpes simplex-chronic ulcers for greater than one month, or bronchitis, pneumonia, or esophagitis\nhistoplasmosis\nisosporiasis (chronic intestinal)\nKaposi’s sarcoma\nlymphoma\nmycobacterium avium complex\ntuberculosis\npneumocystis jirovecii (\ncarinii\n) pneumonia\npneumonia, recurrent\nprogressive multifocal leukoencephalopathy\nsalmonella septicemia, recurrent\ntoxoplasmosis of the brain, and\nwasting syndrome due to HIV.\nReferences\n:  For more information on\nrating AIDs, see\n38 CFR 4.88b\nM21-1, Part V, Subpart iii, 3.4.h\nHIV/AIDS residuals, see\nHIV Basics | HIV/AIDS | CDC\n, and\nHIV/AIDS tests and treatment options, see\nVA HIV/AIDS\n.\nV.iii.3.4.c\n.\nHow HIV Is Diagnosed\nHIV is primarily detected by testing a person’s blood for the presence of antibodies (disease-fighting proteins) to HIV.  Two antibody tests ELISA (enzyme-linked immunosorbent assay) and Western blot assay (a confirmatory test) are used.  An alternative test, IFA (indirect immunofluorescence assay), may also be used.\nThe ELISA and Western blot may be negative for as long as three to six months after exposure to HIV.\nIf a person is highly likely to be infected with HIV, but both tests are negative, a test for the presence of HIV itself in the blood may be done.\nV.iii.3.4.d\n.\nDefinition: CD4 T Cells\nA\nCD4 T\ncell\nis a type of lymphocyte, the white blood cell that bears the major responsibility for the activities of the immune system.  The other major type is the B cell.  Together, they fight off invading viruses, bacteria, parasites, and fungi.  The \"T4,\" \"helper-T,\" or \"CD4\" cell helps regulate and direct immune activity.\nNotes\n:\nA healthy, uninfected person has 800-1200 (or 500 to 1500 by some references) CD4 T cells per cubic millimeter of blood.\nDuring HIV, the number of these cells in the blood progressively declines.\nWhen the count falls below 200, the person is vulnerable to the opportunistic infections and cancers that typify AIDS.\nV.iii.3.4.e\n.\nHIV Transmission\nMajor means of HIV transmission are\nsexual contact\ninfected blood, and\nneedle stick accidents.\nNotes\n:\nNo evidence exists that HIV is transmitted through\nsaliva, sweat, tears, urine, or feces\ncasual contact such as the sharing of food utensils, towels and bedding, swimming pools, telephones, or toilet seats, or\nbiting insects such as mosquitoes, flies, ticks, fleas, bees, wasps, or bedbugs.\nIf there is evidence indicating that the HIV-related illness was the result of intravenous drug abuse, ensure that the authorization activity has conducted a willful misconduct/line-of-duty (LOD) administrative decision prior to rating.\nThere is no presumptive SC provision for HIV.  Veterans must establish SC under other provisions, such as direct SC under\n38 CFR 3.303\nby establishing an in-service event, injury, or disease as the cause of HIV.\nReferences\n:  For more information on\nwillful misconduct and LOD determinations, see\nM21-1, Part X, Subpart iv, 1.C\n, and\nestablishing direct SC, see\nM21-1, Part V, Subpart ii, 2.A\n.\nV.iii.3.4.f\n.\nDefinition: Approved Medication(s)\nWhen rating an HIV case, the term\napproved medication(s)\nincludes treatment regimens and medications prescribed as part of a research protocol at an accredited medical institution.\nV.iii.3.4.g\n.\nRating Considerations for HIV-related Illness\nWhen evaluating HIV-related illness, consider\nseverity and frequency of constitutional symptoms\nuse of approved medication(s)\nT4 cell count, and\nthe development of AIDS-related opportunistic infection or neoplasm.\nNotes\n:\nOnly patients with HIV who are asymptomatic should be rated at 0 percent.\nAn evaluation of 30 percent should be the minimum if there are recurrent constitutional symptoms, even if they have responded to appropriate treatment.\nIn rating HIV, consider the following:\nrating may be based on\n38 CFR 4.88b, DC 6351\ncriteria, or\nseparate evaluations may be warranted under the appropriate diagnostic codes (DCs) if other defined conditions due to HIV infection or its treatment develop.  This could include psychiatric illness, central nervous system manifestations, opportunistic infections, and neoplasms.\nExamples\n:\nEnlarged lymph nodes and fatigue (HIV-related constitutional symptoms) warrant a 10-percent evaluation; however, if pelvic inflammatory disease (PID) or other symptoms develop, the evaluation could go to 30 percent if the symptoms go into remission and then reoccur (recurrent symptoms) or 60 percent if they do not respond to treatment (refractory symptoms).\nIf there is a CD4 count of 400, the Veteran is on HAART (highly active antiretroviral therapy), and there are symptoms of depression but no other significant signs or symptoms of the infection or its treatment, it would be appropriate to assign 10 percent.  However, if the depression rises to the level of a diagnosed major depression or dysthymic disorder, consider evaluating it separately as a secondary condition, with the potential of a higher rating.  The HIV infection would still warrant a 10-percent evaluation under\n38 CFR 4.88b, DC 6351\n, based on findings not related to symptoms of depression—low CD4 count and treatment.\nReference\n:  For more information on avoidance of pyramiding, see\n38 CFR 4.14\nEsteban v. Brown\n, 6 Vet.App. 259 (1994), and\nM21-1, Part V, Subpart ii, 3.D.2.b\n.\nV.iii.3.4.h\n.\nRating AIDS\nOnce a Veteran develops AIDS, evaluate the specific findings based on the table below.\nIn instances of ...\nNote that ...\nopportunistic infections\nonce an AIDS-related opportunistic infection or neoplasm appears, the rating will be 60 percent or above\nmany of the opportunistic infections will warrant a 100- percent evaluation, at least for a time (tuberculosis, lymphoma, etc.), and\nspecial monthly compensation (SMC) will be a frequent consideration.\ncancer\nit should be rated separately, if advantageous to the Veteran, as long as its symptomatologies are not also used to support a 60- or 100-percent evaluation under\n38 CFR 4.88b, DC 6351\n.\nepisodic problems\nthe possibility exists that a particular examination may have been done at a time between episodes of opportunistic infections when findings are relatively few, and\nthe overall history for the past year or so should be considered when rating since some AIDS complications can be episodic.\nReferences\n:  For more information on,\nrating evaluations, see\n38 CFR 4.88b Schedule of Ratings-Infectious Diseases, Immune Disorders and Nutritional Deficiencies\n, and\ntreatment options, see\nHIV Basics | HIV/AIDS | CDC\n, and\nVA HIV/AIDS\n.\n5\n.\nChronic Fatigue Syndrome\nIntroduction\nThis topic contains information about chronic fatigue syndrome, including\ndefinition of chronic fatigue syndrome\n, and\nrating considerations for chronic fatigue syndrome\n.\nChange Date\nAugust 12, 2019\nV.iii.3.5.a\n.\nDefinition:\nChronic Fatigue Syndrome\nChronic fatigue syndrome\nis a complex, multisymptom, debilitating illness characterized by physical and mental manifestations.\nV.iii.3.5.b\n.\nRating Considerations for CFS\nWhen rating a chronic fatigue syndrome case, keep in mind that a diagnosis requires the following:\nnew onset of debilitating fatigue severe enough to reduce daily activity to less than 50 percent of the usual level for at least six months, and\nthe exclusion, by way of a thorough evaluation, of all other clinical conditions that may produce similar symptoms based on history, physical examination, and laboratory tests.\nIn addition, six or more of the following criteria must be met:\nacute onset of the condition\nlow grade fever\nsore throat with no secretions (nonexudative pharyngitis)\npalpable or tender cervical or axillary lymph nodes\ngeneralized muscle aches or weakness\nfatigue lasting 24 hours or longer after exercise\nheadaches (of a type, severity, or pattern that is different from headaches in the pre-morbid state)\nmigratory joint pains\nneuropsychological symptoms, and\nsleep disturbance.\nNote\n:  Consider presumptive SC for chronic fatigue syndrome as a medically unexplained chronic multisymptom illness under\n38 CFR 3.317(a)\n.\nReference\n:  For more information on chronic fatigue syndrome, see\n38 CFR 4.88a\n38 CFR 4.88b\n, and\nM21-1, Part VIII, Subpart ii, 1.A.1.i\n.\n6\n.\nCOVID-19\nIntroduction\nThis topic contains information about rating decisions for COVID-19, including\ndefinition of COVID-19\nuse of the COVID-19 special issue indicator\nactive vs. acute COVID-19\nresiduals of COVID-19\ndelayed onset of COVID-19 residuals\ndisabilities resulting from COVID-19 vaccination\nhospitalization and convalescent ratings for COVID-19 residuals\n, and\napplicable theories of SC for COVID-19 residuals\n.\nChange Date\nAugust 2, 2022\nV.iii.3.6.a\n.\nDefinition:  COVID-19\nNovel Coronavirus (COVID-19)\nis a disease caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  COVID-19 may also be referred to as any of the following:\ncoronavirus, or\ncoronavirus disease.\nNote\n:  Consider claims for SC for COVID-19 under both a presumptive and direct basis.\nReferences\n:  For more information on\npresumptive SC for COVID-19, see\n38 U.S.C. 1164\n, and\nM21-1, Part VIII, Subpart iii, 10\n, and\nconsidering unclaimed theories of SC, see\nM21-1, Part II, Subpart iii, 1.A.2.e\n.\nV.iii.3.6.b\n.\nUse of the COVID-19 Special Issue Indicator\nThe COVID-19 Veterans Benefits Management System contention-based special issue indicator referenced in\nM21-1, Part VIII, Subpart iii, 10.3.a\nshould be used for all COVID-19 claims regardless of the theory of SC being utilized in the claim.\nReference\n:  For more information on the use of special issue indicators, see\nM21-4, Appendix E.2\n.\nV.iii.3.6.c\n.\nActive vs. Acute COVID-19\nCOVID-19 is an acute infectious disease.  As an acute infectious disease, COVID-19 should only be rated based on chronic residual condition(s).  If a Veteran previously had COVID-19 and is currently asymptomatic, deny the claim based on no evidence of a current, chronic disability.\nImportant\n:  Do not arbitrarily determine that a chronic disability is not demonstrated without relying on competent medical evidence.\nReferences\n:  For more information on\nconsidering acute and transitory conditions, see\nM21-1, Part V, Subpart ii, 2.A.1.g\n, and\nhandling allegations of exposure to COVID-19, see\nM21-1, Part VIII, Subpart iii, 10.3.b\n, and\nM21-1, Part II, Subpart iii, 1.C.2.b and c\n.\nV.iii.3.6.d\n.\nResiduals of COVID-19\n38 CFR 4.88b\nadvises to rate any residual disability of infection within the appropriate body system.   As applicable, consider the long-term health effects potentially associated with the infectious disease.  If COVID-19 was diagnosed and resolved during a period of qualifying service or any applicable presumptive period, any chronic residuals attributable to the disease may be SC.\nAssign the most appropriate DC for residuals based on general rating principles.\nSerious long-term complications may include, but are not limited to, the following types of issues:\nrespiratory\ngenitourinary (residuals of acute kidney injury)\ncardiovascular (inflammation of the heart muscle, heart attack, stroke, blood clots)\nskin (rash, hair loss)\naudiological (hearing problems)\nloss of sense of smell and/or taste\nneurological, and\npsychiatric (depression, anxiety, changes in mood).\nImportant\n:\nSince the long-term effects of this disease are still being studied, decision makers must rely on the expertise of medical professionals to determine whether the chronic residual is due to COVID-19.  A medical nexus opinion will generally be required to determine whether a disability is a chronic residual of COVID-19.\nEvaluations for pension purposes must be based on permanent residuals of COVID-19.\nReference\n:  For more information on requesting examinations in claims for SC for residuals of COVID-19, see\nM21-1, Part VIII, Subpart iii, 10.5\n.\nV.iii.3.6.e\n.\nDelayed Onset of COVID-19 Residuals\nPost-COVID-19 conditions are a wide range of new, returning, or ongoing health problems people can experience four weeks or more after first being infected with the virus that causes COVID-19.  If a Veteran is denied SC for COVID-19 due to a lack of a chronic residual disability, a condition may manifest later.\nWhen a new or supplemental claim is submitted for a post-COVID chronic residual that manifested at a later date, consider SC for the claimed issue.  The claim(s) for the post-COVID-19 residual is sufficient new and relevant evidence in a supplemental claim scenario.  Request an examination and/or medical opinion, when otherwise warranted, to link the condition to the prior COVID-19 infection.\nExample 1\n:  A Veteran with an in-service diagnosis of COVID-19 is denied entitlement to compensation because there is no evidence of a chronic residual.  Two months later, a new claim for headaches due to COVID-19 is received.  This is an initial claim for a new issue that may be associated with an in-service event.  Service treatment records are negative for headache complaints.  An exam and medical opinion may be needed to determine whether the claimed headaches are a chronic, post-COVID-19 residual disability.\nExample 2\n:  A Veteran with an in-service diagnosis of COVID-19 is denied entitlement to compensation because there is no evidence of a chronic residual.  Two months later, a supplemental claim for COVID-19 is received with evidence of a new positive COVID-19 test.  There is no allegation or indication of a chronic condition.  The evidence is new and relevant, but continued denial is warranted because there is no evidence of a chronic residual disability.\nReferences\n:  For more information on\nthe definitions of\nnew claim, see\nM21-1, Part I, Subpart i, 1.A.4.i\n, and\nsupplemental claim, see\nM21-1, Part I, Subpart i, 1.A.4.j\n, and\nnew and relevant evidence, see\nM21-1, Part X, Subpart ii, 2.A.2.c\n.\nV.iii.3.6.f\n.\nDisabilities Resulting From COVID-19 Vaccination\nIf evidence establishes that an individual suffers from a disabling condition as result of receiving a COVID-19 vaccination, the disability is subject to SC under the general principles for direct SC.\nNote\n:  If the vaccination-related residual is the result of vaccination received during a period of inactive duty for training (IADT), the individual may be considered disabled by an “injury” incurred during such training.  Consequently, such an individual may be found to have incurred disability, on a direct basis, allowing recognition of the IADT period as a period of active service under\n38 CFR 3.6\n.\nReference\n:  For more information on the requirements for IADT to be considered active service, see\nM21-1, Part V, Subpart ii, 2.A.2.f\n.\nV.iii.3.6.g\n.\nHospitalization and Convalescent Ratings for COVID-19 Residuals\nIf a Veteran is hospitalized due to a complication of COVID-19 for over 21 days, apply the provisions of\n38 CFR 4.29\nto assign a hospital rating.\nAssign the hospital rating for the primary condition that warranted hospitalization.\nIf the primary cause of the hospitalization is unknown, consider reported symptoms and other evidence of record to determine the most appropriate disability for which to assign the hospitalization rating.\nIf the Veteran remains hospitalized at the time the claim is considered, assign an open-ended hospital evaluation as warranted.\nFollowing the hospitalization, assign an appropriate schedular evaluation for any chronic residual, applying\n38 CFR 4.31\nwhen appropriate.\nNote\n:  Application of\n38 CFR 4.30\nrequires surgical treatment, which may occur for treatment of certain COVID-19 residuals.  However, do not apply the provisions of\n38 CFR 4.30(a)(2)\nconcerning the necessity of house confinement to a period of self-quarantine due to COVID-19 since self-quarantine would be unrelated to the surgical treatment.\nReferences\n:  For more information on\nhospitalization ratings, see\nM21-1, Part VIII, Subpart iv, 8.B\n, and\nconvalescent ratings, see\nM21-1, Part VIII, Subpart iv, 8.C\n.\nV.iii.3.6.h\n.\nApplicable Theories of SC for COVID-19 Residuals\nConsider theories of SC for COVID-19 raised by the Veteran or by the evidence of record in accordance with\nM21-1, Part II, Subpart iii, 1.A.2.e\n, and apply the most advantageous theory supported by the evidentiary record.\nReferences\n:  For more information on\nconsidering unclaimed theories of SC, see\nM21-1, Part II, Subpart iii, 1.A.2.e\neffective date considerations specific to presumptive SC for COVID-19, see\nM21-1, Part VIII, Subpart iii, 10.6.f\n, and\nmaximizing effective date determinations, see\nM21-1, Part V, Subpart ii, 4.A.1.i\n.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000014464\" articlename=\"M21-1, Part V, Subpart iii, Chapter 2, Section B - Conditions of the Auditory System\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014464/M21-1-Part-V-Subpart-iii-Chapter-2-Section-B-Conditions-of-the-Auditory-System\">&lt;-- Previous Section</a>  <a articleid=\"554400000180967\" articlename=\"M21-1, Part V, Subpart iii, Chapter 4, Section A - Respiratory Conditions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180967/M21-1-Part-V-Subpart-iii-Chapter-4-Section-A-Respiratory-Conditions\">Next Section --&gt;</a></span></span></p><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><p class=\"ng-scope\"></p><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Chapter</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This chapter contains the following topics: </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"height: 0px; width: 485px; border-spacing: 0px; border-collapse: revert;\" summary=\"Column 1 has the topic number and column 2 has the topic title.\" width=\"485\"><thead><tr><th scope=\"col\" style=\"width: 75px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Topic</strong></span></span></div></th><th scope=\"col\" style=\"width: 345px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Topic Name</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 75px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">1</span></span></div></td><td style=\"width: 345px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1\" target=\"_self\">General Rating Principles for Infectious Diseases, Immune Disorders, and Nutritional Deficiencies</a></span></span></div></td></tr><tr><td style=\"width: 75px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">2</span></span></div></td><td style=\"width: 345px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#2\" target=\"_self\">Tropical Diseases</a></span></span></div></td></tr><tr><td style=\"width: 75px; padding: 0px;\"><div align=\"center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">3</span></span></div></td><td style=\"width: 345px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#3\" target=\"_self\">Rhuematic Fever</a></span></span></div></td></tr><tr><td style=\"width: 75px; text-align: center; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">4</span></span></div></td><td style=\"width: 345px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4\" target=\"_self\">Human Immunodeficiency Virus (HIV)-Related Illness</a></span></span></div></td></tr><tr><td style=\"width: 75px; text-align: center; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">5</span></span></div></td><td style=\"width: 345px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#5\" target=\"_self\">Chronic Fatigue Syndrome</a></span></span></div></td></tr><tr><td style=\"width: 75px; text-align: center; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">6</span></span></div></td><td style=\"width: 345px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#6\" target=\"_self\">Novel Coronavirus Infection (COVID-19)</a></span></span></div></td></tr></tbody></table><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><h2 class=\"ng-scope\"> <br/> </h2><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial, helvetica, sans-serif\">1<a id=\"1\" name=\"1\">.</a>  General Rating Principles for Infectious Diseases, Immune Disorders, and Nutritional Deficiencies</span></span></h2><div class=\"ng-scope\"></div><div class=\"ng-scope\"></div><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about the general rating principles for infectious diseases, immune disorders, and nutritional deficiencies, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">definition of</span></span></div><ul><li><div><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">infectious diseases</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1b\" target=\"_self\">immune disorders</a>, and</span></span></div></li><li><div><a href=\"#1c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">nutritional deficiencies</span></span></a></div></li></ul></li><li><div><a href=\"#1d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">revisions of the infectious diseases, immune disorders, and nutritional deficiencies rating schedule</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1e\" target=\"_self\">evaluations under the infectious diseases general rating formula</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#1f\" target=\"_self\">evaluating long-term health effects of 38 CFR 3.317 infectious diseases</a>. </span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">August 12, 2019</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.1.a<a id=\"1a\" name=\"1a\">.</a>  Definition:  Infectious Diseases </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Infectious diseases</em></strong> are disorders caused by organisms, such as bacteria, viruses, fungi, or parasites.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em><strong>Example</strong></em>:  Malaria.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Consider presumptive service connection (SC) for infectious diseases listed in</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&amp;mc=true&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(b)</a> based on tropical service</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&amp;mc=true&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(c)</a> based on confirmed former prisoner of war (FPOW) status, and </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=fceaf1ee49593eb14b52cd65ba2cc0ff&amp;mc=true&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317(c)</a> based on service in the Southwest Asia theater of operations during the Gulf War or on or after September 19, 2001, in Afghanistan.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on presumptive SC for</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">tropical diseases, see <a articleid=\"554400000177449\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 1 - Service Connection (SC) for Tropical Diseases\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177449/M21-1-Part-VIII-Subpart-iii-Chapter-1-Service-Connection-SC-for-Tropical-Diseases\">M21-1, Part VIII, Subpart iii, 1</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">FPOW disabilities, see <a articleid=\"554400000177473\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 2, Section D - Rating Claims Based on Former Prisoner of War (FPOW) Status\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177473/M21-1-Part-VIII-Subpart-iv-Chapter-2-Section-D-Rating-Claims-Based-on-Former-Prisoner-of-War-FPOW-Status\">M21-1, Part VIII, Subpart iv, 2.D</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">infectious diseases under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=fceaf1ee49593eb14b52cd65ba2cc0ff&amp;mc=true&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317</a>, see <a articleid=\"554400000177434\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 1, Section A - General Information on Presumptive Service Connection (SC) for Persian Gulf Veterans\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177434/M21-1-Part-VIII-Subpart-ii-Chapter-1-Section-A-General-Information-on-Presumptive-Service-Connection-SC-for-Persian-Gulf-Veterans\">M21-1, Part VIII, Subpart ii, 1.A.1.p</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.1.b<a id=\"1b\" name=\"1b\">.</a>  Definition:  Immune Disorders </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Immune</em></strong><em> <strong>disorders </strong></em>cause abnormally low activity or overactivity of the immune system.  In cases of immune system overactivity, the body attacks and damages its own tissues (autoimmune diseases).  Immune deficiency diseases decrease the body's ability to fight invaders, causing vulnerability to infections.  Immune disorders can be caused by organisms, use of medications, or other chronic conditions.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example</em></strong>:  Systemic lupus erythematosus.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Consider presumptive SC for immune disorders listed in <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&amp;mc=true&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(a)</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.1.c<a id=\"1c\" name=\"1c\">.</a>  Definition:  Nutritional Deficiencies </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Nutritional deficiencies</em></strong> occur when the body is unable to obtain the necessary amount of a nutrient that is required for proper health.  These deficiencies can be caused by diet, surgical residuals, genetics, environment, or other diseases.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Example</em></strong>:  Beriberi.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Consider presumptive SC for disabilities listed in SC <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&amp;mc=true&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(c)</a> based on based on confirmed FPOW status.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on presumptive SC for FPOW disabilities, see <a articleid=\"554400000177473\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 2, Section D - Rating Claims Based on Former Prisoner of War (FPOW) Status\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177473/M21-1-Part-VIII-Subpart-iv-Chapter-2-Section-D-Rating-Claims-Based-on-Former-Prisoner-of-War-FPOW-Status\">M21-1, Part VIII, Subpart iv, 2.D.3</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.1.d<a id=\"1d\" name=\"1d\">.</a>  Revisions of the Infectious Diseases, Immune Disorders, and Nutritional Deficiencies Rating Schedule </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The criteria for rating disabilities based on infectious diseases, immune disorders, and nutritional deficiencies in <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=4cce411a2e5d5b189807cc42c846cc91&amp;mc=true&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b</a> were most recently updated effective</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">August 11, 2019, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">August 30, 1996.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The purpose of these updates was to</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">incorporate medical advances</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">update medical terminology</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">add disabilities not previously included, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">refine rating criteria.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  These updates were not liberalizing changes in the rating criteria.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">these and other historical changes to <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=4cce411a2e5d5b189807cc42c846cc91&amp;mc=true&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b</a>, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=17a7d596f39f14c4ff2256382742f829&amp;mc=true&amp;node=ap38.1.4_1150.a&amp;rgn=div9\" target=\"_blank\">38 CFR 4, Appendix A</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=4a1a4a3e8d501895071cbe0d16cf437e&amp;pitd=20190726&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b</a> (Historical), and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the <a href=\"http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3aproject=lsa-bva-counsel-judge-project&amp;v%3asources=lsa-bva-citator-regulation-collection&amp;frontpage=1&amp;v%3aframe=form&amp;\" target=\"_blank\">Board of Veterans Appeal Research Tools</a> website for historical <a href=\"http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3Asources=lsa-bva-citator-regulation-collection&amp;v%3Aproject=lsa-bva-counsel-judge-project&amp;lnquery=4.88b&amp;lnfilters=&amp;chkbxfilters=&amp;query=%284.88b%29&amp;querytype=boolean\" target=\"_blank\">38 CFR 4.88b</a>, and</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">effect of rating schedule readjustment, see <a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\">M21-1, Part V, Subpart ii, 3.D.2.i</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.1.e<a id=\"1e\" name=\"1e\">.</a>  Evaluations Under the Infectious Diseases General Rating Formula </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Prior to the August 11, 2019, rating schedule revision, each infectious disease listed under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=4cce411a2e5d5b189807cc42c846cc91&amp;mc=true&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b</a> had its own prescribed rating criteria. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Effective August 11, 2019, <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=4cce411a2e5d5b189807cc42c846cc91&amp;mc=true&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b</a> contains a general rating formula applicable to multiple infectious diseases, regardless of etiology.  </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">For each diagnostic code (DC) that refers to this general rating formula, decision makers must</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">assign the prescribed evaluation during the active disease phase, and thereafter, </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">assign</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">a 0-percent evaluation for the infectious disease under the relevant <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=4cce411a2e5d5b189807cc42c846cc91&amp;mc=true&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b</a> DC, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">evaluations for any residual disability of the infection within the appropriate body system as indicated by the notes in the evaluation criteria. </span></span></div></li></ul></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Regardless of whether resolution occurs spontaneously or because of treatment, long-term disability in such situations results from residual functional impairment of the body systems affected by the infectious disease, rather than the infection itself.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Infectious diseases for both the initial diagnosis and any relapse of active infection must be confirmed by diagnostic testing specific to the disease.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.1.f<a id=\"1f\" name=\"1f\">.</a>  Evaluating Long-Term Health Effects of 38 CFR 3.317 Infectious Diseases </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">As applicable, consider the long-term health effects potentially associated with infectious diseases as listed in <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=fceaf1ee49593eb14b52cd65ba2cc0ff&amp;mc=true&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317(d)</a>, specifically for brucellosis, Campylobacter jejuni, Coxiella burnetii (Q fever), malaria, Mycobacterium tuberculosis, nontyphoid Salmonella, Shigella, visceral leishmaniasis, and West Nile virus.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on presumptive SC for infectious diseases under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=fceaf1ee49593eb14b52cd65ba2cc0ff&amp;mc=true&amp;node=se38.1.3_1317&amp;rgn=div8\" target=\"_blank\">38 CFR 3.317</a>, see <a articleid=\"554400000177434\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 1, Section A - General Information on Presumptive Service Connection (SC) for Persian Gulf Veterans\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177434/M21-1-Part-VIII-Subpart-ii-Chapter-1-Section-A-General-Information-on-Presumptive-Service-Connection-SC-for-Persian-Gulf-Veterans\">M21-1, Part VIII, Subpart ii, 1.A.1.p</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"></div><p class=\"ng-scope\" style=\"text-align: left\"> <br/><br/> <span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>2<a id=\"2\" name=\"2\">.</a></strong><strong>  Tropical Diseases</strong></span></span><br/> <br/> </p><div class=\"ng-scope\"></div><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Introduction</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information about tropical diseases, including</span></span></p><ul><li><a href=\"#2a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">specific tropical diseases</span></span></a></li><li><a href=\"#2b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">obtaining information about tropical diseases</span></span></a></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2c\" target=\"_self\">incubation periods of tropical diseases</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#2d\" target=\"_self\">considering SC for tropical diseases not of record</a>.</span></span></li></ul></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Change Date</strong></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">December 13, 2005</span></span></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.3.2.a<a id=\"2a\" name=\"2a\">.</a> Specific Tropical Diseases</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The following tropical diseases, among others, may require attention in view of their incidence in areas of foreign service:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">bacterial infections, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">bacillary dysentery</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cholera</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Hansen’s disease (leprosy)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Oroya fever</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">pinta</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">plague</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">relapsing fever, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">yaws</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">viral infections, including yellow fever</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">roundworm parasitic infections, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">dracontiasis</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">filariasis (Bancroft’s type)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">hookworm infection</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">loiasis, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">onchocerciasis</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">other parasitic infections, including</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">amebiasis</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">blackwater fever</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">leishmaniasis</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">malaria, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">schistosomiasis.</span></span></div></li></ul></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em><strong>Notes</strong></em>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Rate amebiasis and schistosomiasis under the digestive system.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Rate pinta, verruga peruana (a late residual of Oroya fever), onchoceriasis, oriental sore, and espundia (Old World cutaneous and American (New World) mucocutaneous leishmaniasis) under diseases of the skin.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on tropical diseases, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&amp;mc=true&amp;node=se38.1.3_1307&amp;rgn=div8\" target=\"_blank\">38 CFR 3.307(a)(4)</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&amp;mc=true&amp;node=se38.1.3_1309&amp;rgn=div8\" target=\"_blank\">38 CFR 3.309(b)</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000177449\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 1 - Service Connection (SC) for Tropical Diseases\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177449/M21-1-Part-VIII-Subpart-iii-Chapter-1-Service-Connection-SC-for-Tropical-Diseases\">M21-1, Part VIII, Subpart iii, 1</a>.</span></span></div></li></ul></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.3.2.b<a id=\"2b\" name=\"2b\">.</a> Obtaining Information about Tropical Diseases</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">An understanding of the locality, incubation period, and residuals of tropical diseases may be obtained from standard treatises.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em><strong>Reference</strong></em>: For more information on tropical diseases, see <em><a href=\"http://www.merckmanuals.com/professional/index.html\" target=\"_blank\"><em>The Merck Manual of Diagnosis and Therapy</em></a>.</em></span></span></div></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.3.2.c<a id=\"2c\" name=\"2c\">.</a> Incubation Periods of Tropical Diseases</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The table below contains the incubation periods of some tropical diseases.</span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"border-spacing: 0px; border-collapse: revert;\" summary=\"Column 1 provides the tropical disease and column 2 provides the incubation period.\"><thead><tr><th scope=\"col\" style=\"width: 252px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Tropical Disease</strong></span></span></div></th><th scope=\"col\" style=\"width: 252px; padding: 0px;\"><div style=\"text-align: center\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>Incubation Period</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">dracontiasis (Guinea worm disease)</span></span></div></td><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">14 months</span></span></div></td></tr><tr><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">filariasis, Bancroft’s type</span></span></div></td><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">up to 8 to 12 months</span></span></div></td></tr><tr><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">kala-azar (visceral leishmaniasis)</span></span></div></td><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">up to one year</span></span></div></td></tr><tr><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Hansen’s disease (leprosy)</span></span></div></td><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">five years or more</span></span></div></td></tr><tr><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">loiasis, calabar swelling</span></span></div></td><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">three years</span></span></div></td></tr><tr><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">oriental sore, Old World cutaneous leishmaniasis</span></span></div></td><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">up to 18 months</span></span></div></td></tr></tbody></table><div></div></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.3.2.d<a id=\"2d\" name=\"2d\">.</a> Considering SC for Tropical Diseases Not of Record</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">When considering SC for tropical diseases <em>not</em> of record during service always</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">consider tropical residence other than that during military service, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">consult standard texts for disease factors, such as</span></span><ul style=\"list-style-type: circle\"><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">locality of confinement</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">early symptoms</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">course of the disease, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">periods of incubation.</span></span></li></ul></li></ul><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong><em>Reference</em></strong>:<strong><em>  </em></strong>For more information on developing claims for SC for tropical diseases, see <a articleid=\"554400000177449\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 1 - Service Connection (SC) for Tropical Diseases\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177449/M21-1-Part-VIII-Subpart-iii-Chapter-1-Service-Connection-SC-for-Tropical-Diseases\">M21-1, Part VIII, Subpart iii, 1</a>.</span></span></p></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div><p><br/> </p></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>3<a id=\"3\" name=\"3\">.</a>  Rheumatic Fever</strong></span></span></h2><p class=\"ng-scope\"><br/> </p><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information about rheumatic fever, including</span></span></p><ul><li><a href=\"#3a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">definition of rheumatic fever</span></span></a></li><li><a href=\"#3b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">complications of rheumatic fever</span></span></a></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#3c\" target=\"_self\">the prognosis of rheumatic fever</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#3d\" target=\"_self\">considering the effects of rheumatic heart disease</a>.</span></span></li></ul></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">December 13, 2005</span></span></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.3.3.a<a id=\"3a\" name=\"3a\">.</a> Definition: Rheumatic Fever</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Rheumatic fever is an acute, subacute, or chronic systemic disease that, for unknown reasons, is self-limiting or may lead to slowly progressive valve deformity of the heart.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on evaluating rheumatic fever, see <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=4cce411a2e5d5b189807cc42c846cc91&amp;mc=true&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b, DC 6309</a>.</span></span></div></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.3.3.b<a id=\"3b\" name=\"3b\">.</a> Complications of Rheumatic Fever</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Complications of rheumatic fever include</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">cardiac arrhythmias</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pericarditis</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">rheumatic pneumonitis</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pulmonary embolism</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">pulmonary infarction</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">valve deformity, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">in extreme cases, congestive heart failure.</span></span></li></ul></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.3.3.c<a id=\"3c\" name=\"3c\">.</a> Prognosis of Rheumatic Fever</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">The prognosis is good in cases of rheumatic fever.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">If the age of onset is postadolescence, residual heart damage</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">occurs in less than 20 percent of the cases, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">is generally less severe than if the onset is during childhood.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><em><strong>Note</strong></em>:<em><strong>  </strong></em>Mitral valve insufficiency is the most common residual.</span></span></div></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"height: 8px; width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">V.iii.3.3.d<a id=\"3d\" name=\"3d\">.</a> Considering the Effects of Rheumatic Heart Disease</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"height: 8px; width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">For more information on the effects of rheumatic heart disease, see </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=4cce411a2e5d5b189807cc42c846cc91&amp;mc=true&amp;node=se38.1.4_1104&amp;rgn=div8\" target=\"_blank\">38 CFR 4.104, DC 7000</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000014520\" articlename=\"M21-1, Part V, Subpart iii, Chapter 5 - Cardiovascular System Conditions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014520/M21-1-Part-V-Subpart-iii-Chapter-5-Cardiovascular-System-Conditions\">M21-1, Part V, Subpart iii, 5.1.g</a>.</span></span></div></li></ul></td></tr></tbody></table><div align=\"center\" class=\"ng-scope\"><div style=\"margin-left: 85pt\"><hr/></div><br/> </div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>4<a id=\"4\" name=\"4\">.</a>  HIV-Related Illness</strong></span></span></h2><p class=\"ng-scope\"><br/> </p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">This topic contains information about HIV-related illness, including </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">definition of </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4a\" target=\"_self\">HIV</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4b\" target=\"_self\">acquired immunodeficiency syndrome (AIDS)</a></span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4c\" target=\"_self\">how HIV infection is diagnosed</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4d\" target=\"_self\">definition of CD4 T cells</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4e\" target=\"_self\">HIV transmission</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4f\" target=\"_self\">definition of approved medication(s)</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4g\" target=\"_self\">rating considerations for HIV-related illness</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4h\" target=\"_self\">rating AIDS</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">August 12, 2019</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"height: 95px; width: 655px; border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.4.a<a id=\"4a\" name=\"4a\">.</a> Definition:<br/>HIV</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 507px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Human immunodeficiency virus</em></strong> (HIV) is spread through body fluids that affect specific cells of the immune system, called CD4 cells, or T cells.  Over time, HIV can destroy so many of these cells that the body cannot fight off infections and disease.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on rating HIV, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=b24d4b4bbeed8036aa9263ef5ebeb4a1&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#4g\" target=\"_self\">M21-1, Part V, Subpart iii, 3.4.g</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"height: 639px; width: 655px; border-spacing: 0px; border-collapse: revert;\" width=\"655\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.4.b<a id=\"4b\" name=\"4b\">.</a>  Definition:  AIDS</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"height: 9px; width: 511px; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Acquired immunodeficiency syndrome</em></strong> (AIDS) is a secondary infection and results from HIV infection.  It is not a single distinct disease, but rather a disorder characterized by a severe suppression of the immune system, rendering the body susceptible to and unable to fight off a variety of normally manageable infections, cancers, and other diseases. </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Patients with AIDS suffer infections called “opportunistic” because they take the opportunity to attack when the immune system is weak.  This may involve the intestinal tract, lungs, brain, eyes and other organs, as well as debilitating weight loss, diarrhea, and neurologic conditions.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Important</em></strong>:  If a Veteran has HIV and one or more of the following opportunistic infections, regardless of the CD4 (T4) count, the Veteran is considered to have a diagnosis of AIDS:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">candidiasis of the bronchi, trachea, esophagus, or lungs</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">invasive cervical cancer</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">coccidioidomycosis </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cryptococcosis </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cryptosporidiosis </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cytomegalovirus (particularly CMV retinitis) </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">HIV-related encephalopathy </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">herpes simplex-chronic ulcers for greater than one month, or bronchitis, pneumonia, or esophagitis </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">histoplasmosis </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">isosporiasis (chronic intestinal) </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Kaposi’s sarcoma</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">lymphoma</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">mycobacterium avium complex </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">tuberculosis </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">pneumocystis jirovecii (<em>carinii</em>) pneumonia </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">pneumonia, recurrent </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">progressive multifocal leukoencephalopathy </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">salmonella septicemia, recurrent</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">toxoplasmosis of the brain, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">wasting syndrome due to HIV.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">rating AIDs, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=b24d4b4bbeed8036aa9263ef5ebeb4a1&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b</a> </span></span></div></li><li><div><a href=\"#4h\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">M21-1, Part V, Subpart iii, 3.4.h</span></span></a></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">HIV/AIDS residuals, see <a href=\"http://www.cdc.gov/hiv/basics/index.html\" target=\"_blank\">HIV Basics | HIV/AIDS | CDC</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">HIV/AIDS tests and treatment options, see <a href=\"http://www.hiv.va.gov/\" target=\"_blank\">VA HIV/AIDS</a>.</span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"height: 201px; width: 654px; border-spacing: 0px; border-collapse: revert;\" width=\"654\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.4.c<a id=\"4c\" name=\"4c\">.</a>  How HIV Is Diagnosed</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 498px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">HIV is primarily detected by testing a person’s blood for the presence of antibodies (disease-fighting proteins) to HIV.  Two antibody tests ELISA (enzyme-linked immunosorbent assay) and Western blot assay (a confirmatory test) are used.  An alternative test, IFA (indirect immunofluorescence assay), may also be used.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">The ELISA and Western blot may be negative for as long as three to six months after exposure to HIV.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If a person is highly likely to be infected with HIV, but both tests are negative, a test for the presence of HIV itself in the blood may be done.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"height: 234px; width: 655px; border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.4.d<a id=\"4d\" name=\"4d\">.</a>  Definition: CD4 T Cells</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 498px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">A <strong><em>CD4 T</em></strong> <strong><em>cell</em></strong> is a type of lymphocyte, the white blood cell that bears the major responsibility for the activities of the immune system.  The other major type is the B cell.  Together, they fight off invading viruses, bacteria, parasites, and fungi.  The \"T4,\" \"helper-T,\" or \"CD4\" cell helps regulate and direct immune activity.</span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><em><strong>Notes</strong></em>:</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">A healthy, uninfected person has 800-1200 (or 500 to 1500 by some references) CD4 T cells per cubic millimeter of blood. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">During HIV, the number of these cells in the blood progressively declines. </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When the count falls below 200, the person is vulnerable to the opportunistic infections and cancers that typify AIDS. </span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"height: 108px; width: 658px; border-spacing: 0px; border-collapse: revert;\" width=\"658\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.4.e<a id=\"4e\" name=\"4e\">.</a>  HIV Transmission</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 498px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Major means of HIV transmission are</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sexual contact</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">infected blood, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">needle stick accidents.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">No evidence exists that HIV is transmitted through</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">saliva, sweat, tears, urine, or feces</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">casual contact such as the sharing of food utensils, towels and bedding, swimming pools, telephones, or toilet seats, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">biting insects such as mosquitoes, flies, ticks, fleas, bees, wasps, or bedbugs.</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If there is evidence indicating that the HIV-related illness was the result of intravenous drug abuse, ensure that the authorization activity has conducted a willful misconduct/line-of-duty (LOD) administrative decision prior to rating.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">There is no presumptive SC provision for HIV.  Veterans must establish SC under other provisions, such as direct SC under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&amp;mc=true&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303</a> by establishing an in-service event, injury, or disease as the cause of HIV.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">willful misconduct and LOD determinations, see <a articleid=\"554400000177987\" articlename=\"M21-1, Part X, Subpart iv, Chapter 1, Section C  - Willful Misconduct and Line of Duty (LOD)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177987/M21-1-Part-X-Subpart-iv-Chapter-1-Section-C-Willful-Misconduct-and-Line-of-Duty-LOD\">M21-1, Part X, Subpart iv, 1.C</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">establishing direct SC, see <a articleid=\"554400000180481\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section A - Direct Service Connection (SC) and Service Incurrence of an Injury\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180481/M21-1-Part-V-Subpart-ii-Chapter-2-Section-A-Direct-Service-Connection-SC-and-Service-Incurrence-of-an-Injury\">M21-1, Part V, Subpart ii, 2.A</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"height: 140px; width: 658px; border-spacing: 0px; border-collapse: revert;\" width=\"658\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.4.f<a id=\"4f\" name=\"4f\">.</a>  Definition: Approved Medication(s)</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 498px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When rating an HIV case, the term <strong><em>approved medication(s)</em></strong> includes treatment regimens and medications prescribed as part of a research protocol at an accredited medical institution.  </span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"width: 657px; border-spacing: 0px; border-collapse: revert;\" width=\"657\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.4.g<a id=\"4g\" name=\"4g\">.</a>  Rating Considerations for HIV-related Illness</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 512px; vertical-align: top; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When evaluating HIV-related illness, consider</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">severity and frequency of constitutional symptoms</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">use of approved medication(s)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">T4 cell count, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the development of AIDS-related opportunistic infection or neoplasm.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Notes</em></strong>: </span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Only patients with HIV who are asymptomatic should be rated at 0 percent. </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">An evaluation of 30 percent should be the minimum if there are recurrent constitutional symptoms, even if they have responded to appropriate treatment.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In rating HIV, consider the following:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">rating may be based on <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=b24d4b4bbeed8036aa9263ef5ebeb4a1&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b, DC 6351</a> criteria, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">separate evaluations may be warranted under the appropriate diagnostic codes (DCs) if other defined conditions due to HIV infection or its treatment develop.  This could include psychiatric illness, central nervous system manifestations, opportunistic infections, and neoplasms.</span></span></div></li></ul></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Examples</em></strong>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Enlarged lymph nodes and fatigue (HIV-related constitutional symptoms) warrant a 10-percent evaluation; however, if pelvic inflammatory disease (PID) or other symptoms develop, the evaluation could go to 30 percent if the symptoms go into remission and then reoccur (recurrent symptoms) or 60 percent if they do not respond to treatment (refractory symptoms).</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">If there is a CD4 count of 400, the Veteran is on HAART (highly active antiretroviral therapy), and there are symptoms of depression but no other significant signs or symptoms of the infection or its treatment, it would be appropriate to assign 10 percent.  However, if the depression rises to the level of a diagnosed major depression or dysthymic disorder, consider evaluating it separately as a secondary condition, with the potential of a higher rating.  The HIV infection would still warrant a 10-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=b24d4b4bbeed8036aa9263ef5ebeb4a1&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b, DC 6351</a>, based on findings not related to symptoms of depression—low CD4 count and treatment.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on avoidance of pyramiding, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=557fe860e9ed20916f342aeec564b03b&amp;mc=true&amp;node=se38.1.4_114&amp;rgn=div8\" target=\"_blank\">38 CFR 4.14</a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000066775\" articlename=\"Esteban v. Brown, February 25, 1994, 6 Vet.App. 259 (1994)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000066775/Esteban-v-Brown-February-25-1994-6-VetApp-259-1994\"><em>Esteban v. Brown</em></a>, 6 Vet.App. 259 (1994), and </span></span></div></li><li><div><a articleid=\"554400000180489\" articlename=\"M21-1, Part V, Subpart ii, Chapter 3, Section D - Evaluating Disabilities\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180489/M21-1-Part-V-Subpart-ii-Chapter-3-Section-D-Evaluating-Disabilities\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">M21-1, Part V, Subpart ii, 3.D.2.b</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">.</span></span></div></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"height: 793px; width: 651px; border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.4.h<a id=\"4h\" name=\"4h\">.</a>  Rating AIDS</span></span></h3></td><td style=\"height: 8px; width: 15px; vertical-align: top; padding: 0px;\"></td><td style=\"width: 504px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">Once a Veteran develops AIDS, evaluate the specific findings based on the table below.</span></span></div><div></div><table border=\"1\" cellpadding=\"0\" cellspacing=\"0\" style=\"height: 546px; width: 477px; border-spacing: 0px; border-collapse: revert;\" summary=\"This is an in-note table.  Column 1 provides the instances and column 2 provides the information to note.\" width=\"477\"><thead><tr><th scope=\"col\" style=\"width: 258px; padding: 0px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>In instances of ...</strong></span></span></div></th><th scope=\"col\" style=\"width: 252px; padding: 0px;\"><div style=\"text-align: left\"><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong>Note that ...</strong></span></span></div></th></tr></thead><tbody><tr><td style=\"width: 258px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">opportunistic infections</span></span></div></td><td style=\"width: 252px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">once an AIDS-related opportunistic infection or neoplasm appears, the rating will be 60 percent or above</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">many of the opportunistic infections will warrant a 100- percent evaluation, at least for a time (tuberculosis, lymphoma, etc.), and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">special monthly compensation (SMC) will be a frequent consideration.</span></span></div></li></ul></td></tr><tr><td style=\"width: 258px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">cancer</span></span></div></td><td style=\"width: 252px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">it should be rated separately, if advantageous to the Veteran, as long as its symptomatologies are not also used to support a 60- or 100-percent evaluation under <a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=b24d4b4bbeed8036aa9263ef5ebeb4a1&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b, DC 6351</a>.</span></span></div></td></tr><tr><td style=\"width: 258px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">episodic problems</span></span></div></td><td style=\"width: 252px; padding: 0px;\"><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the possibility exists that a particular examination may have been done at a time between episodes of opportunistic infections when findings are relatively few, and </span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the overall history for the past year or so should be considered when rating since some AIDS complications can be episodic.</span></span></div></li></ul></td></tr></tbody></table><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>References</em></strong>:  For more information on,</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">rating evaluations, see <a href=\"http://vbaw.vba.va.gov/bl/21/Publicat/Regs/Part4/4_88b.htm\" target=\"_blank\">38 CFR 4.88b Schedule of Ratings-Infectious Diseases, Immune Disorders and Nutritional Deficiencies</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">treatment options, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.cdc.gov/hiv/basics/index.html\" target=\"_blank\">HIV Basics | HIV/AIDS | CDC</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.hiv.va.gov/\" target=\"_blank\">VA HIV/AIDS</a>.</span></span></div></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">                <br/>                 </span></span></div><p class=\"ng-scope\" style=\"margin-left: 85pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">                               </span></span></p><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\"><strong>5<a id=\"5\" name=\"5\">.</a>  Chronic Fatigue Syndrome</strong></span></span></h2><p class=\"ng-scope\"></p><p class=\"ng-scope\" style=\"margin-left: 85pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">      </span></span></p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></p></td><td style=\"width: 516px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information about chronic fatigue syndrome, including</span></span></p><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#5a\" target=\"_self\">definition of chronic fatigue syndrome</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#5b\" target=\"_self\">rating considerations for chronic fatigue syndrome</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">August 12, 2019</span></span></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.5.a<a id=\"5a\" name=\"5a\">.</a> Definition:<br/>Chronic Fatigue Syndrome</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></p></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Chronic fatigue syndrome</em></strong> is a complex, multisymptom, debilitating illness characterized by physical and mental manifestations.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">V.iii.3.5.b<a id=\"5b\" name=\"5b\">.</a>  Rating Considerations for CFS</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"><p><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"> </span></span></p></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">When rating a chronic fatigue syndrome case, keep in mind that a diagnosis requires the following:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">new onset of debilitating fatigue severe enough to reduce daily activity to less than 50 percent of the usual level for at least six months, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">the exclusion, by way of a thorough evaluation, of all other clinical conditions that may produce similar symptoms based on history, physical examination, and laboratory tests.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">In addition, six or more of the following criteria must be met:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">acute onset of the condition</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">low grade fever</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sore throat with no secretions (nonexudative pharyngitis)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">palpable or tender cervical or axillary lymph nodes</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">generalized muscle aches or weakness</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">fatigue lasting 24 hours or longer after exercise</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">headaches (of a type, severity, or pattern that is different from headaches in the pre-morbid state)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">migratory joint pains</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">neuropsychological symptoms, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\">sleep disturbance.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Note</em></strong>:  Consider presumptive SC for chronic fatigue syndrome as a medically unexplained chronic multisymptom illness under <a href=\"https://www.ecfr.gov/cgi-bin/text-idx?SID=620878ea26128501e61f0dcee5419cb9&amp;mc=true&amp;tpl=/ecfrbrowse/Title38/38cfr3_main_02.tpl\" target=\"_blank\">38 CFR 3.317(a)</a>.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><strong><em>Reference</em></strong>:  For more information on chronic fatigue syndrome, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=ae97f740618da48a7a1781cd4615b1f4&amp;node=se38.1.4_188a&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88a </a></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=ae97f740618da48a7a1781cd4615b1f4&amp;node=se38.1.4_188b&amp;rgn=div8\" target=\"_blank\">38 CFR 4.88b</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial, helvetica, sans-serif\"><a articleid=\"554400000177434\" articlename=\"M21-1, Part VIII, Subpart ii, Chapter 1, Section A - General Information on Presumptive Service Connection (SC) for Persian Gulf Veterans\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177434/M21-1-Part-VIII-Subpart-ii-Chapter-1-Section-A-General-Information-on-Presumptive-Service-Connection-SC-for-Persian-Gulf-Veterans\">M21-1, Part VIII, Subpart ii, 1.A.1.i</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"></div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial, helvetica, sans-serif\">6<a id=\"6\" name=\"6\">.</a>  COVID-19</span></span></h2><div class=\"ng-scope\"></div><div class=\"ng-scope\"></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">This topic contains information about rating decisions for COVID-19, including</span></span></div><ul><li><a href=\"#6a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">definition of COVID-19</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"> </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#6b\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">use of the COVID-19 special issue indicator</span></span></a> </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#6c\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">active vs. acute COVID-19</span></span></a> </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#6d\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">residuals of COVID-19</span></span></a> </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#6e\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">delayed onset of COVID-19 residuals</span></span></a> </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#6f\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">disabilities resulting from COVID-19 vaccination</span></span></a> </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#6g\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">hospitalization and convalescent ratings for COVID-19 residuals</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">, and</span></span> </span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"#6h\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">applicable theories of SC for COVID-19 residuals</span></span></a><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">. </span></span> </span></span></li></ul></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">August 2, 2022</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.3.6.a<a id=\"6a\" name=\"6a\">.</a>  Definition:  COVID-19 </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em>Novel Coronavirus (COVID-19)</em> is a disease caused by a virus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).  COVID-19 may also be referred to as any of the following:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">coronavirus, or</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">coronavirus disease.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Note</strong></em>:  Consider claims for SC for COVID-19 under both a presumptive and direct basis.  </span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>References</strong></em>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">presumptive SC for COVID-19, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"https://www.law.cornell.edu/uscode/text/38/1164\" target=\"_blank\">38 U.S.C. 1164</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000203897\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 10 - Presumptive Service Connection (SC) for Coronavirus Disease (COVID-19)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000203897/M21-1-Part-VIII-Subpart-iii-Chapter-10-Presumptive-Service-Connection-SC-for-Coronavirus-Disease-COVID-19\">M21-1, Part VIII, Subpart iii, 10</a>, and</span></span></div></li></ul></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">considering unclaimed theories of SC, see <a articleid=\"554400000174869\" articlename=\"M21-1, Part II, Subpart iii, Chapter 1, Section A - Applications for Benefits\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000174869/M21-1-Part-II-Subpart-iii-Chapter-1-Section-A-Applications-for-Benefits\">M21-1, Part II, Subpart iii, 1.A.2.e</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.3.6.b<a id=\"6b\" name=\"6b\">.</a>  Use of the COVID-19 Special Issue Indicator </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">The COVID-19 Veterans Benefits Management System contention-based special issue indicator referenced in <a articleid=\"554400000203897\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 10 - Presumptive Service Connection (SC) for Coronavirus Disease (COVID-19)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000203897/M21-1-Part-VIII-Subpart-iii-Chapter-10-Presumptive-Service-Connection-SC-for-Coronavirus-Disease-COVID-19\">M21-1, Part VIII, Subpart iii, 10.3.a</a> should be used for all COVID-19 claims regardless of the theory of SC being utilized in the claim.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on the use of special issue indicators, see <a articleid=\"554400000179710\" articlename=\"Appendix E. Index of Corporate Flashes and Special Issues\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000179710/Appendix-E-Index-of-Corporate-Flashes-and-Special-Issues\">M21-4, Appendix E.2</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.3.6.c<a id=\"6c\" name=\"6c\">.</a>  Active vs. Acute COVID-19 </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">COVID-19 is an acute infectious disease.  As an acute infectious disease, COVID-19 should only be rated based on chronic residual condition(s).  If a Veteran previously had COVID-19 and is currently asymptomatic, deny the claim based on no evidence of a current, chronic disability.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Important</strong></em>:  Do not arbitrarily determine that a chronic disability is not demonstrated without relying on competent medical evidence.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>References</strong></em>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">considering acute and transitory conditions, see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 2.A.1.g</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">handling allegations of exposure to COVID-19, see</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000203897\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 10 - Presumptive Service Connection (SC) for Coronavirus Disease (COVID-19)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000203897/M21-1-Part-VIII-Subpart-iii-Chapter-10-Presumptive-Service-Connection-SC-for-Coronavirus-Disease-COVID-19\">M21-1, Part VIII, Subpart iii, 10.3.b</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a articleid=\"554400000174872\" articlename=\"M21-1, Part II, Subpart iii, Chapter 1, Section C - Screening Applications for Substantial Completeness and Notification Requirements\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000174872/M21-1-Part-II-Subpart-iii-Chapter-1-Section-C-Screening-Applications-for-Substantial-Completeness-and-Notification-Requirements\">M21-1, Part II, Subpart iii, 1.C.2.b and c</a>. </span></span></div></li></ul></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.3.6.d<a id=\"6d\" name=\"6d\">.</a>  Residuals of COVID-19</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4#4.88b\" target=\"_blank\">38 CFR 4.88b</a> advises to rate any residual disability of infection within the appropriate body system.   As applicable, consider the long-term health effects potentially associated with the infectious disease.  If COVID-19 was diagnosed and resolved during a period of qualifying service or any applicable presumptive period, any chronic residuals attributable to the disease may be SC.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Assign the most appropriate DC for residuals based on general rating principles.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Serious long-term complications may include, but are not limited to, the following types of issues:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">respiratory</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">genitourinary (residuals of acute kidney injury)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">cardiovascular (inflammation of the heart muscle, heart attack, stroke, blood clots)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">skin (rash, hair loss)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">audiological (hearing problems)</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">loss of sense of smell and/or taste</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">neurological, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">psychiatric (depression, anxiety, changes in mood).</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Important</strong></em>:</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Since the long-term effects of this disease are still being studied, decision makers must rely on the expertise of medical professionals to determine whether the chronic residual is due to COVID-19.  A medical nexus opinion will generally be required to determine whether a disability is a chronic residual of COVID-19.</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Evaluations for pension purposes must be based on permanent residuals of COVID-19.</span></span></div></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on requesting examinations in claims for SC for residuals of COVID-19, see <a articleid=\"554400000203897\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 10 - Presumptive Service Connection (SC) for Coronavirus Disease (COVID-19)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000203897/M21-1-Part-VIII-Subpart-iii-Chapter-10-Presumptive-Service-Connection-SC-for-Coronavirus-Disease-COVID-19\">M21-1, Part VIII, Subpart iii, 10.5</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.3.6.e<a id=\"6e\" name=\"6e\">.</a>  Delayed Onset of COVID-19 Residuals </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Post-COVID-19 conditions are a wide range of new, returning, or ongoing health problems people can experience four weeks or more after first being infected with the virus that causes COVID-19.  If a Veteran is denied SC for COVID-19 due to a lack of a chronic residual disability, a condition may manifest later.</span></span></div><div><span style=\"font-size: 14px\"> </span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">When a new or supplemental claim is submitted for a post-COVID chronic residual that manifested at a later date, consider SC for the claimed issue.  The claim(s) for the post-COVID-19 residual is sufficient new and relevant evidence in a supplemental claim scenario.  Request an examination and/or medical opinion, when otherwise warranted, to link the condition to the prior COVID-19 infection.</span></span></div><div><span style=\"font-size: 14px\"> </span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Example 1</strong></em>:  A Veteran with an in-service diagnosis of COVID-19 is denied entitlement to compensation because there is no evidence of a chronic residual.  Two months later, a new claim for headaches due to COVID-19 is received.  This is an initial claim for a new issue that may be associated with an in-service event.  Service treatment records are negative for headache complaints.  An exam and medical opinion may be needed to determine whether the claimed headaches are a chronic, post-COVID-19 residual disability.</span></span></div><div><span style=\"font-size: 14px\"> </span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Example 2</strong></em>:  A Veteran with an in-service diagnosis of COVID-19 is denied entitlement to compensation because there is no evidence of a chronic residual.  Two months later, a supplemental claim for COVID-19 is received with evidence of a new positive COVID-19 test.  There is no allegation or indication of a chronic condition.  The evidence is new and relevant, but continued denial is warranted because there is no evidence of a chronic residual disability.</span></span></div><div><span style=\"font-size: 14px\"> </span></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>References</strong></em>:  For more information on</span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">the definitions of</span> </span><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">new claim, see <a articleid=\"554400000181474\" articlename=\"M21-1, Part I, Subpart i, Chapter 1, Section A - Description and General Information on Duty to Notify and Duty to Assist\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000181474/M21-1-Part-I-Subpart-i-Chapter-1-Section-A-Description-and-General-Information-on-Duty-to-Notify-and-Duty-to-Assist\">M21-1, Part I, Subpart i, 1.A.4.i</a>, and</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">supplemental claim, see <a articleid=\"554400000181474\" articlename=\"M21-1, Part I, Subpart i, Chapter 1, Section A - Description and General Information on Duty to Notify and Duty to Assist\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000181474/M21-1-Part-I-Subpart-i-Chapter-1-Section-A-Description-and-General-Information-on-Duty-to-Notify-and-Duty-to-Assist\">M21-1, Part I, Subpart i, 1.A.4.j</a>, and</span></span></li></ul></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">new and relevant evidence, see <a articleid=\"554400000177963\" articlename=\"M21-1, Part X, Subpart ii, Chapter 2, Section A - Revision Based on Specific Types of Submissions, Including Supplemental Claims\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177963/M21-1-Part-X-Subpart-ii-Chapter-2-Section-A-Revision-Based-on-Specific-Types-of-Submissions-Including-Supplemental-Claims\">M21-1, Part X, Subpart ii, 2.A.2.c</a>.</span></span></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.3.6.f<a id=\"6f\" name=\"6f\">.</a>  Disabilities Resulting From COVID-19 Vaccination </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If evidence establishes that an individual suffers from a disabling condition as result of receiving a COVID-19 vaccination, the disability is subject to SC under the general principles for direct SC.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Note</strong></em>:  If the vaccination-related residual is the result of vaccination received during a period of inactive duty for training (IADT), the individual may be considered disabled by an “injury” incurred during such training.  Consequently, such an individual may be found to have incurred disability, on a direct basis, allowing recognition of the IADT period as a period of active service under <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFRf5fe31f49d4f511/section-3.6\" target=\"_blank\">38 CFR 3.6</a>.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Reference</strong></em>:  For more information on the requirements for IADT to be considered active service, see <a articleid=\"554400000014383\" articlename=\"M21-1, Part V, Subpart ii, Chapter 1, Section A - Principles of Reviewing and Weighing Evidence\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014383/M21-1-Part-V-Subpart-ii-Chapter-1-Section-A-Principles-of-Reviewing-and-Weighing-Evidence\">M21-1, Part V, Subpart ii, 2.A.2.f</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.3.6.g<a id=\"6g\" name=\"6g\">.</a>  Hospitalization and Convalescent Ratings for COVID-19 Residuals </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If a Veteran is hospitalized due to a complication of COVID-19 for over 21 days, apply the provisions of <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.29\" target=\"_top\">38 CFR 4.29</a> to assign a hospital rating.                      </span></span></div><ul><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Assign the hospital rating for the primary condition that warranted hospitalization.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If the primary cause of the hospitalization is unknown, consider reported symptoms and other evidence of record to determine the most appropriate disability for which to assign the hospitalization rating.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">If the Veteran remains hospitalized at the time the claim is considered, assign an open-ended hospital evaluation as warranted.</span></span></li><li><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Following the hospitalization, assign an appropriate schedular evaluation for any chronic residual, applying <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.31\" target=\"_blank\">38 CFR 4.31</a> when appropriate.</span></span></li></ul><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>Note</strong></em>:  Application of <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.30\" target=\"_blank\">38 CFR 4.30</a> requires surgical treatment, which may occur for treatment of certain COVID-19 residuals.  However, do not apply the provisions of <a href=\"https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.30\" target=\"_blank\">38 CFR 4.30(a)(2)</a> concerning the necessity of house confinement to a period of self-quarantine due to COVID-19 since self-quarantine would be unrelated to the surgical treatment.</span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>References</strong></em>:  For more information on</span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">hospitalization ratings, see <a articleid=\"554400000177479\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 8, Section B - Hospitalization Ratings Under 38 CFR 4.29\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177479/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-B-Hospitalization-Ratings-Under-38-CFR-429\">M21-1, Part VIII, Subpart iv, 8.B</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">convalescent ratings, see <a articleid=\"554400000177542\" articlename=\"M21-1, Part VIII, Subpart iv, Chapter 8, Section C - Convalescent Ratings Under 38 CFR 4.30\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177542/M21-1-Part-VIII-Subpart-iv-Chapter-8-Section-C-Convalescent-Ratings-Under-38-CFR-430\">M21-1, Part VIII, Subpart iv, 8.C</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">V.iii.3.6.h<a id=\"6h\" name=\"6h\">.</a>  Applicable Theories of SC for COVID-19 Residuals </span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; vertical-align: top; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">Consider theories of SC for COVID-19 raised by the Veteran or by the evidence of record in accordance with <a articleid=\"554400000174869\" articlename=\"M21-1, Part II, Subpart iii, Chapter 1, Section A - Applications for Benefits\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000174869/M21-1-Part-II-Subpart-iii-Chapter-1-Section-A-Applications-for-Benefits\">M21-1, Part II, Subpart iii, 1.A.2.e</a><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">, and apply the most advantageous theory supported by the evidentiary record.</span></span></span></span></div><div></div><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><em><strong>References</strong></em>:  For more information on</span></span></span></span></div><ul><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">considering unclaimed theories of SC, see <a articleid=\"554400000174869\" articlename=\"M21-1, Part II, Subpart iii, Chapter 1, Section A - Applications for Benefits\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000174869/M21-1-Part-II-Subpart-iii-Chapter-1-Section-A-Applications-for-Benefits\">M21-1, Part II, Subpart iii, 1.A.2.e</a></span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">effective date considerations specific to presumptive SC for COVID-19, see <a articleid=\"554400000203897\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 10 - Presumptive Service Connection (SC) for Coronavirus Disease (COVID-19)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000203897/M21-1-Part-VIII-Subpart-iii-Chapter-10-Presumptive-Service-Connection-SC-for-Coronavirus-Disease-COVID-19\">M21-1, Part VIII, Subpart iii, 10.6.f</a>, and</span></span></span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: Arial, Helvetica, sans-serif\">maximizing effective date determinations, see <a articleid=\"554400000180492\" articlename=\"M21-1, Part V, Subpart ii, Chapter 4, Section A - Effective Dates\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180492/M21-1-Part-V-Subpart-ii-Chapter-4-Section-A-Effective-Dates\">M21-1, Part V, Subpart ii, 4.A.1.i</a>.</span></span></span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><p class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a articleid=\"554400000014464\" articlename=\"M21-1, Part V, Subpart iii, Chapter 2, Section B - Conditions of the Auditory System\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000014464/M21-1-Part-V-Subpart-iii-Chapter-2-Section-B-Conditions-of-the-Auditory-System\">&lt;-- Previous Section</a>  <a articleid=\"554400000180967\" articlename=\"M21-1, Part V, Subpart iii, Chapter 4, Section A - Respiratory Conditions\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180967/M21-1-Part-V-Subpart-iii-Chapter-4-Section-A-Respiratory-Conditions\">Next Section --&gt;</a></span></span></p><p class=\"ng-scope\"><span style=\"font-family: arial, helvetica, sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3Asources=lsa-bva-citator-regulation-collection&v%3Aproject=lsa-bva-counsel-judge-project&lnquery=4.88b&lnfilters=&chkbxfilters=&query=%284.88b%29&querytype=boolean",
    "http://vacoappbva2.dva.va.gov/lsa/cgi-bin/query-meta.exe?v%3aproject=lsa-bva-counsel-judge-project&v%3asources=lsa-bva-citator-regulation-collection&frontpage=1&v%3aframe=form&",
    "http://vbaw.vba.va.gov/bl/21/Publicat/Regs/Part4/4_88b.htm",
    "http://www.cdc.gov/hiv/basics/index.html",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=557fe860e9ed20916f342aeec564b03b&mc=true&node=se38.1.4_114&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=ae97f740618da48a7a1781cd4615b1f4&node=se38.1.4_188a&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=ae97f740618da48a7a1781cd4615b1f4&node=se38.1.4_188b&rgn=div8",
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=b24d4b4bbeed8036aa9263ef5ebeb4a1&node=se38.1.4_188b&rgn=div8",
    "http://www.hiv.va.gov/",
    "http://www.merckmanuals.com/professional/index.html",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=17a7d596f39f14c4ff2256382742f829&mc=true&node=ap38.1.4_1150.a&rgn=div9",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&mc=true&node=se38.1.3_1303&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&mc=true&node=se38.1.3_1307&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=1fa2e8f6ac23caebe8a1ce9a908e9bf6&mc=true&node=se38.1.3_1309&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=4a1a4a3e8d501895071cbe0d16cf437e&pitd=20190726&node=se38.1.4_188b&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=4cce411a2e5d5b189807cc42c846cc91&mc=true&node=se38.1.4_1104&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=4cce411a2e5d5b189807cc42c846cc91&mc=true&node=se38.1.4_188b&rgn=div8",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=620878ea26128501e61f0dcee5419cb9&mc=true&tpl=/ecfrbrowse/Title38/38cfr3_main_02.tpl",
    "https://www.ecfr.gov/cgi-bin/text-idx?SID=fceaf1ee49593eb14b52cd65ba2cc0ff&mc=true&node=se38.1.3_1317&rgn=div8",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-3/subpart-A/subject-group-ECFRf5fe31f49d4f511/section-3.6",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4#4.88b",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.29",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.30",
    "https://www.ecfr.gov/current/title-38/chapter-I/part-4/subpart-A/section-4.31",
    "https://www.law.cornell.edu/uscode/text/38/1164"
  ],
  "scraped_at": "2025-06-16T22:44:20.990940",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180967/M21-1-Part-V-Subpart-iii-Chapter-4-Section-A-Respiratory-Conditions"
}